Xu Hailiang, Feng Yunyun, Jia Zhankui, Yang Jinjian, Lu Xueren, Li Jun, Xia Mingliang, Wu Chunru, Zhang Yonggang, Chen Jianhua
Department of Urinary Surgery, The Zhumadian City Center Hospital, Zhumadian, Henan 463000, P.R. China.
Department of Pediatrics, The Zhumadian City Center Hospital, Zhumadian, Henan 463000, P.R. China.
Oncol Lett. 2017 Jul;14(1):981-986. doi: 10.3892/ol.2017.6214. Epub 2017 May 19.
Axis inhibition protein 1 (AXIN1) is characterized as a tumor suppressor in numerous types of cancer. However, the functional role of AXIN1 in the testicular germ cell tumors (TGCTs) remains unclear. The human embryonal carcinoma-derived cell line NTera2 was transfected with a recombinant AXIN1 expression vector (pcDNA3.1-AXIN1) and/or a small interfering RNA (siRNA) directed against AXIN1 (siAXIN). Following transfection, the mRNA and protein levels of AXIN1 were determined via reverse transcription-quantitative polymerase chain reaction analysis and western blotting, respectively. In addition, cell viability, apoptosis and the expression of apoptosis-associated proteins [apoptosis regulator Bax (Bax) and B-cell lymphoma (Bcl)-2] and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway proteins [phosphorylated (p)-mTOR, mTOR, p-AKT, AKT, P-70S ribosomal protein S6 (S6) and S6] were assessed. AXIN1 mRNA and protein levels were increased following transfection with pcDNA3.1-AXIN1 and decreased following transfection with siAXIN1 compared with their respective control groups. After overexpression of AXIN1, NTera2 cell viability and expression of Bcl-2, p-mTOR p-AKT and p-S6 protein was decreased, while apoptosis and Bax protein levels were increased, compared with the control group. However, there was no significant difference in AXIN1 mRNA expression, apoptosis or Bax/Bcl-2 protein expression when NTera2 cells were simultaneously transfected with pcDNA3.1-AXIN1+siAXIN1. In conclusion, the results of the present study indicate that overexpression of AXIN1 protects against TGCTs via inhibiting the PI3K/AKT/mTOR signaling pathway, suggesting that AXIN1 may be a potential target for gene therapy in TGCTs.
轴抑制蛋白1(AXIN1)在多种癌症中被视为肿瘤抑制因子。然而,AXIN1在睾丸生殖细胞肿瘤(TGCTs)中的功能作用仍不清楚。用重组AXIN1表达载体(pcDNA3.1 - AXIN1)和/或针对AXIN1的小干扰RNA(siRNA)(siAXIN)转染人胚胎癌衍生细胞系NTera2。转染后,分别通过逆转录定量聚合酶链反应分析和蛋白质印迹法测定AXIN1的mRNA和蛋白质水平。此外,评估细胞活力、凋亡以及凋亡相关蛋白[凋亡调节因子Bax(Bax)和B细胞淋巴瘤(Bcl)-2]和磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(AKT)/雷帕霉素哺乳动物靶蛋白(mTOR)信号通路蛋白[磷酸化(p)-mTOR、mTOR、p-AKT、AKT、P-70S核糖体蛋白S6(S6)和S6]的表达。与各自的对照组相比,用pcDNA3.1 - AXIN1转染后AXIN1的mRNA和蛋白质水平升高,用siAXIN1转染后降低。AXIN1过表达后,与对照组相比,NTera2细胞活力以及Bcl-2、p-mTOR、p-AKT和p-S6蛋白的表达降低,而凋亡和Bax蛋白水平升高。然而,当NTera2细胞同时用pcDNA3.1 - AXIN1 + siAXIN1转染时,AXIN1 mRNA表达、凋亡或Bax/Bcl-2蛋白表达没有显著差异。总之,本研究结果表明,AXIN1的过表达通过抑制PI3K/AKT/mTOR信号通路对TGCTs具有保护作用,提示AXIN1可能是TGCTs基因治疗的潜在靶点。